FDA Stymied By Reauthorization Terms That May Slow Ingredient Development
This article was originally published in The Tan Sheet
Executive Summary
FDA is stumped on interpreting and enforcing a provision in the FDA Amendments Act of 2007 that could have a chilling effect on development of new functional food and dietary supplement ingredients, an FDA official and an industry leader say
You may also be interested in...
Congress Did Not Intend FDAAA Sec. 912 To Apply To Supplements – Industry
FDA should not subject dietary supplements to an FDA Amendment Act of 2007 provision that, if interpreted broadly, would block supplement sales, restrict innovation and discourage pre-market safety and efficacy tests, industry leaders say
Congress Did Not Intend FDAAA Sec. 912 To Apply To Supplements – Industry
FDA should not subject dietary supplements to an FDA Amendment Act of 2007 provision that, if interpreted broadly, would block supplement sales, restrict innovation and discourage pre-market safety and efficacy tests, industry leaders say
Congress Did Not Intend FDAAA Sec. 912 To Apply To Supplements – Industry
FDA should not subject dietary supplements to an FDA Amendment Act of 2007 provision that, if interpreted broadly, would block supplement sales, restrict innovation and discourage pre-market safety and efficacy tests, industry leaders say